I'm based in the US and work in the Biotech sector. we are...

I'm based in the US and work in the Biotech sector. we are starting to hear about major slowdowns or even halting clinical development programs altogether. Patients can't come into clinic, all non-essential appointments are cancelled. A colleague running a neuro study (lead investigator) is expecting at least 6 months gap in data and many patients lost to follow up. Has anyone with an ear close to the ground got any idea if patients are still being treated with on the LAVENDER study? Might be too early to get any clear answers but I'd suggest keeping a close eye on how this plays out and impacts clinical development for the sector in general.